May 2, 2023
BURLINGTON, Ontario – May 2, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) is pleased to announce that on May 1, 2023, staff of the Ontario Securities Commission (the “OSC”) granted a full revocation of the failure-to-file cease trade order (“FFCTO”)...
April 14, 2023
BURLINGTON, Ontario – April 14, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that further to the review by the Ontario Securities Commission (“OSC”) of the Company’s continuous disclosure record, and a subsequent request from staff of the OSC in...
April 14, 2023
BURLINGTON, Ontario – April 14, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is announcing changes to its board of directors. Jason Lewis has resigned as a director of the...
February 1, 2023
BURLINGTON, Ontario – February 1, 2023 – On Friday, January 27, 2023, Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), filed its financial results for the fiscal year ended February 28, 2022. Now that the Company has completed the filing of its audited...
February 1, 2023
BURLINGTON, Ontario – February 1, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), has filed its financial results for the first three quarters of the 2023 fiscal year. Now that the Company has completed the filing of its audited financial statements...
January 17, 2023
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – January 17, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...
January 10, 2023
BURLINGTON, Ontario – January 10, 2023 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated December 20, 2022, the Company and its auditors are continuing to...
December 29, 2022
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – December 29, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...
December 21, 2022
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – December 20, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...
December 12, 2022
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order BURLINGTON, Ontario – December 12, 2022 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release...